Results 51 to 60 of about 3,791 (213)

Evaluation of carrier added (CA) and no carrier added (NCA) 177Lu radionuclide roles in radiolabeling of peptide groups [PDF]

مجله علوم و فنون هسته‌ای, 2020
The peptides radiolabeled with 177Lu are including a wide range of promising radiopharmaceuticals. The NCA form of 177Lu provides a high specific activity that is required in targeted receptor therapy in order to avoid saturation of the targeted ...
S. Vosoughi, N. Salek, M. Ghannadi Maragheh   +2 more
doaj   +1 more source

¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence. [PDF]

Endocr Oncol
Introduction 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) represents a possible therapeutic option for patients with metastatic inoperable phaeochromocytomas (PCC) and paragangliomas (PGL) who demonstrate adequate somatostatin analogue ...
Shekhda KM, Armeni E, Xu Y, D'afflitto M, Hayes A, Mandair D, Yu D, Quigley AM, Navalkissoor S, Gnanasegaran G, Grossman AB, Caplin M, Toumpanakis C, Khoo B.   +13 more
europepmc   +2 more sources

Uncovering G Protein‐Coupled Receptors: Novel Targets and Biomarkers for Predicting Glioma Prognosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Low‐grade gliomas (LGG) exhibit significant heterogeneity and recurrence risk. G protein‐coupled receptors (GPCR) contribute to glioma malignant progression, but their prognostic value remains unclear. This work attempts to formulate a GPCR‐based outcome‐predicting model for LGG. Methods Based on TCGA LGG data, the enrichment scores
Jun Yang, Dongxu Zhang, Dongyuan Liu, Da Lin, Hao Wang   +4 more
wiley   +1 more source

The Safety and Efficacy of the Repeated PRRT with [90Y]Y/[177Lu]Lu-DOTATATE in Patients with NET

International Journal of Endocrinology, 2021
Purpose. The peptide receptor radionuclide therapy (PRRT) is a treatment option for patients with disseminated, inoperable G1 and G2 neuroendocrine tumours (NETs).
Anna Zemczak, Paweł Gut, Dariusz Pawlak, Maciej Kołodziej, Leszek Królicki, Beata Kos-Kudła, Marek Ruchała, Grzegorz Kamiński, Jolanta Kunikowska   +8 more
doaj   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

EJNMMI Research, 2019
Background The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking.
Madhav Prasad Yadav, Sanjana Ballal, Chandrasekhar Bal   +2 more
doaj   +1 more source

Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE

Endocrine Connections, 2021
Background: Monitoring of pancreatic neuroendocrine tumors (PanNET) undergoing peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE depends on changes in tumor size, which often occur late.
Olof Joakim Pettersson, Katarzyna Fröss-Baron, Joakim Crona, Anders Sundin   +3 more
doaj   +1 more source

Inhibition of SIRT7 Overcomes Radioresistance in Pancreatic Neuroendocrine Tumors by Reactivating MEN1 Expression

Advanced Science, EarlyView.
Pancreatic neuroendocrine tumors frequently silence MEN1 through epigenetic mechanisms. Here, SIRT7 recruits DNMT1 to the MEN1 promoter, drives hypermethylation, and enhances DNA repair. Inhibiting SIRT7 restores MEN1, reduces MRN complex abundance, impairs double‐strand break repair, and sensitizes PanNET models to radiation, supporting SIRT7 as a ...
Jianyun Jiang, Yan Wang, Yi Qin, Luohai Chen, Xiaowu Xu, Guixiong Fan, Desheng Jing, Miaoyan Wei, Xianjun Yu, Junfeng Xu, Shunrong Ji, Jie Chen   +11 more
wiley   +1 more source

Advanced Molecular Imaging Probes for Skeletal Diseases: Current Progress and Future Perspectives

iRADIOLOGY, EarlyView.
This review summarizes the potential molecular imaging techniques and probes for common orthopedic diseases, such as trauma, infection, metabolism, tumor, joint, spine and other fields, aiming to provide a basis for the development of a new generation of molecular imaging probes.
Shuo Guo, Yuling Cui, Zhiye Fan, Chenxin Jiang, Bowen Fu, Guangbin Cui, Yanli He   +6 more
wiley   +1 more source

Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE

EJNMMI Physics, 2022
Purpose Recent reports personalizing the administered activity (AA) of each cycle of peptide receptor radionuclide therapy based on the predicted absorbed dose (AD) to the kidneys (dose-limiting organ) have been promising.
Javian C. Malcolm, Nadia Falzone, Jennifer E. Gains, Matthew D. Aldridge, David Mirando, Boon Q. Lee, Mark N. Gaze, Katherine A. Vallis   +7 more
doaj   +1 more source